Suzetrigine in Total Hip Arthroplasty
A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty
Hospital for Special Surgery, New York
210 participants
Nov 3, 2025
INTERVENTIONAL
Conditions
Summary
Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).
Eligibility
Inclusion Criteria5
- Patients undergoing primary THA (posterior approach) with participating surgeons
- Age 18 to 80 years old
- Planned discharge to home
- Planned use of neuraxial anesthesia
- American Society of Anesthesiologists (ASA) Physical Status 1 - 3
Exclusion Criteria13
- ASA greater than 3
- Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)
- History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)
- History of QT prolongation
- Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device
- Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse
- Inability to comply with any component of the study protocol
- Younger than 18 or greater than 80 years old at the time of enrollment
- Patient already on Suzetrigine
- Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease/Child Pugh B or C, use of strong CYP3 inhibitors or inducers)
- Contraindications to neuraxial anesthesia or any other part of the study protocol
- Participation in another investigational drug or device study
- Pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Suzetrigine is a new novel peripherally acting non-opioid pain medication recently approved by the FDA that exerts its analgesic effects by binding to the peripherally located Nav1.8 Sodium channel receptors present on peripheral nerves.
This will be a placebo drug.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07226700